Curriculum Vitae

DR. HEH CHOON HAN

Pharmacy Lecturer
  • Department of Pharmaceutical Chemistry
    Faculty of Pharmacy
  • 0379677835

BIOGRAPHY

Interested in computer-aided drug discovery. Developed Self-Evolving Peptide Algorithm (SEPA) for the better virtual screening of potential peptides towards specific drug target. SEPA is available here:

https://drive.google.com/drive/folders/1aEmCaSIkXdEJcAX8X1qPNJrzhBGSKv7p

AREAS OF EXPERTISE

  • DRUG DISCOVERY
    Molecular Docking, Enzymatic Assay, Rational Drug Discovery and Design

ACADEMIC QUALIFICATION

  • PhD, (Pharmacy)
    Universiti Malaya (UM)
  • MSc.IT, (Information Systems, Technology & Management)
    Universiti Sains Malaysia (Usm)
  • BPharm, (Pharmacy)
    Universiti Sains Malaysia (Usm)

ADMINISTRATIVE DUTIES

  • Head of Department
    01 Jan 2024 - present (Department of Pharmaceutical Chemistry, Faculty of Pharmacy)
  • Head of Department
    16 Sep 2021 - 31 Dec 2023 (Department of Pharmaceutical Chemistry, Faculty of Pharmacy)
  • Head of Department
    16 Sep 2019 - 15 Sep 2021 (Department of Pharmaceutical Chemistry, Faculty of Pharmacy)
  • Module coordinator - Drug Literacy (MIB3019)
    10 Sep 2018 - 08 Sep 2019 (Department of Pharmacy, Faculty of Medicine)
  • Module coordinator - Pharmaceutical Product Development (MIB3017/MWEF3106)
    21 Jul 2017 - 20 Jul 2018 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Pharmaceutical Product Deveopment (MWEF3106)
    21 Jul 2016 - 20 Jul 2017 (Department of Pharmacy, Faculty of Medicine)
  • Committee member for Academic Quality Assurance
    21 Jul 2016 - 20 Jul 2017 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Basic Pharmaceutical Chemistry (MIB1001)
    21 Jul 2015 - 21 Jul 2016 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Physical Pharmacy (MIB1008/MWEF1107)
    22 Feb 2016 - 20 Jul 2016 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Pharmaceutical Product Development (MWEF3106)
    21 Jul 2015 - 20 Jul 2016 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Preparation of department documents for accreditation by the Pharmacy Board
    28 Aug 2014 - 31 Dec 2015 (Department of Pharmacy, Faculty of Medicine)
  • Quality Manager
    01 Sep 2015 - 31 Dec 2015 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Pharmacy Department Webpage
    28 Aug 2014 - 20 Jul 2015 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Physical Pharmcy (MWEF1107)
    28 Aug 2014 - 20 Jul 2015 (Department of Pharmacy, Faculty of Medicine)
  • Coordinator - Pharmaceutical Product Development (MWEF3106)
    28 Aug 2014 - 20 Jul 2015 (Department of Pharmacy, Faculty of Medicine)

MEMBERSHIPS

  • PROFESSIONAL MEMBERSHIP OF MALAYSIA SOCIETY OF COSMETIC SCIENTIST, MEMBER
    2023 to 2024 (National)
  • ACTA TOPICA, ELSEVIER, REVIEWER
    Since 2014 (International)

PUBLICATIONS

Article in Journal
WoS
  1. Tasnim, Jarin; Hashim, Najihah Mohd; Han, Heh Choon (2024). A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors, CELL BIOCHEMISTRY AND FUNCTION. 42(2). doi:10.1002/cbf.3967
  2. Chan, Yi Wei; Tan, Choo Hock; Heh, Choon Han; Tan, Kae Yi (2023). An immunoinformatic approach to assessing the immunogenic capacity of alpha-neurotoxins in elapid snake venoms, FRONTIERS IN PHARMACOLOGY. 14. doi:10.3389/fphar.2023.1143437
  3. Tan, Ke Han; Chin, Sek Peng; Heh, Choon Han (2022). Automated in silico EGFR Peptide Inhibitor Elongation using Self-evolving Peptide Algorithm, CURRENT COMPUTER-AIDED DRUG DESIGN. 18(2), 150-158. doi:10.2174/1573409918666220516144300
  4. Tan, Wan Chein; Othman, Shatrah; Lim, See Khai; Rashid, Nurshamimi Nor; Heh, Choon Han (2022). A Reverse Structure-based Design of HPV E7 Inhibitor, CURRENT COMPUTER-AIDED DRUG DESIGN. 18(4), 318-325. doi:10.2174/1573409918666220509214449
  5. Wong, Chen Yuan; Leong, Kok Hoong; He, Xuemei; Zheng, Fengjing; Sun, Jian; Wang, Zhenxing; Heh, Choon Han; Kong, Kin Weng (2022). Phytochemicals of six selected herbal plants and their inhibitory activities towards free radicals and glycation, FOOD BIOSCIENCE. 46. doi:10.1016/j.fbio.2022.101557
  6. Abdulwahab, M. K., Tan, K. H., Dzulkeflee, R., Leong, K. H., Heh, C. H., & Ariffin, A. (2021). In-silico Studies of the Antiproliferative Activity of New Anilinoquinazoline Derivatives Against NSCLC Cells. Journal of Molecular Structure, 1228, 13. doi: 10.1016/j.molstruc.2020.129786
  7. Anasamy, T., Chee, C. F., Wong, Y. E. F., Heh, C. H., Kiew, L. V., Lee, H. B., & Chung, L. Y. (2021). Triorganotin complexes in cancer chemotherapy: Mechanistic insights and future perspectives. Applied Organometallic Chemistry, 35(2), 33. doi: 10.1002/aoc.6089
  8. Kiew, L. V., Chang, C. Y., Huang, S. Y., Wang, P. W., Heh, C. H., Liu, C. T., . . . Chang, C. C. (2021). Development of flexible electrochemical impedance spectroscopy-based biosensing platform for rapid screening of SARS-CoV-2 inhibitors. Biosensors & Bioelectronics, 183, 10. doi: 10.1016/j.bios.2021.113213
  9. Lim, S. K., Othman, R., Yusof, R., & Heh, C. H. (2021). Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes. Chemical Biology & Drug Design, 97(1), 28-40. doi: 10.1111/cbdd.13756
  10. Shi, H., Ishikawa, R., Heh, C. H., Sasaki, S., & Taniguchi, Y. (2021). Development of MTH1-Binding Nucleotide Analogs Based on 7,8-Dihalogenated 7-Deaza-dG Derivatives. International Journal of Molecular Sciences, 22(3), 13. doi: 10.3390/ijms22031274
  11. Abdulwahab, M. K., Dzulkeflee, R., Han, T. K., Ruslan, R. A., Leong, K. H., Heh, C. H., & Ariffin, A. (2020). Synthesis, In Vitro Antiproliferative Activity, and In Silico Studies of New Anilinoquinazoline Derivatives as Potential AntitumorAgents. Russian Journal of General Chemistry, 90(12), 2410-2418. doi: 10.1134/s1070363220120294
Others
  1. Adib Afandi Abdullah, Yean Kee Lee, Sek Peng Chin, See Khai Lim, Vannajan Sanghiran Lee, Rozana Othman, Shatrah Othman, Noorsaadah Abdul Rahman, Rohana Yusof and Choon Han Heh. (2020). Discovery of Dengue Virus Inhibitors, Current Medicinal Chemistry, 27: 4945-5036.
  2. Thavoncharoensub N, Maruyama K, Heh CH, Leong KH, Shi H, Shigematsu Y, Sasaki S, Taniguchi Y (2019) Synthesis of c-N-modified 8-oxo-2 -deoxyguanosine triphosphate and its characterization. Nucleosides, Nucleotides and Nucleic Acids. 38(8), 578-589.
  3. Bujang, N. B., Chee, C. F., Heh, C. H., Rahman, N. A., & Buckle, M. J. (2017). Phosphodiesterase-5 inhibitors and their analogues as adulterants of herbal and food products: analysis of the Malaysian market in 2014-2016. Food Additives & Contaminants: Part A, null-null. doi: 10.1080/19440049.2017.1336674
  4. Gan, C. S., Lee, Y. K., Heh, C. H., Rahman, N. A., Yusof, R., & Othman, S. (2017). The synthetic molecules YK51 and YK73 attenuate replication of dengue virus serotype 2. Tropical Biomedicine, 34(2), 270-283.
  5. Gan, C. S., Lim, S. K., Chee, C. F., Yusof, R., & Heh, C. H. (2017). Sofosbuvir as treatment against dengue? Chem Biol Drug Des. doi: 10.1111/cbdd.13091
  6. Lim, S., Othman, R., Yusof, R., & Heh, C. (2016). Rational drug discovery of HCV helicase inhibitor: Improved docking accuracy with multiple seedings of Autodock Vina and in situ minimization. Curr Comput Aided Drug Des., 13(2), 160-169.
  7. Ching Chin Lee, Fatimah Harun, Muhammad Yazid Jalaludin, Choon Han Heh, Rozana Othman, Sarni Mat Junit. Prevalence of c.2268dup and detection of two novel alterations, c.670_672del and c.1186C>T, in the TPO gene in a cohort of Malaysian Chinese with thyroid dyshormonogenesis. BMJ Open 2015;5:e006121. doi:10.1136/bmjopen- 2014-006121
  8. Ching Chin Lee, Fatimah Harun, Muhammad Yazid Jalaludin, Choon Han Heh, Rozana Othman, In Nee Kang, and Sarni Mat Junit. Variable clinical phenotypes in a family with homozygous c.1159G>A mutation in the thyroid peroxidase gene. Hormone Research in Paediatrics (2014) 81: 356-360 DOI:10.1159/000359922)
  9. Heh, C. H., Othman, R., Buckle, M. J., Sharifuddin, Y., Yusof, R., & Rahman, N. A. (2013). Rational discovery of dengue type 2 non-competitive inhibitors. Chem Biol Drug Des, 82(1), 1-11. doi: 10.1111/cbdd.12122
  10. Lee, C. C., Harun, F., Jalaludin, M. Y., Heh, C. H., Othman, R., & Mat Junit, S. (2013). A Novel, Homozygous c.1502T>G (p.Val501Gly) Mutation in the Thyroid peroxidase Gene in Malaysian Sisters with Congenital Hypothyroidism and Multinodular Goiter. Int J Endocrinol, 2013, 987186.
  11. Eng-Chong, T., Yean-Kee, L., Chin-Fei, C., Choon-Han, H., Sher-Ming, W., Li-Ping, C. T., . . . Yusof, R. (2012). Boesenbergia rotunda: From Ethnomedicine to Drug Discovery. Evid Based Complement Alternat Med, 2012, 473637.
  12. Rothan, H., Han, H. C., Ramasamy, T. S., Othman, S., Rahman, N. A., & Yusof, R. (2012). Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infectious Diseases, 12(1), 314.
Chapter in Books
  1. Heh, C.H., Othman, R., Yusof, R., Rahman, N. A. (2016) Rational Drug Discovery: Virtual Screening of DEN-2 Non-competitive Inhibitors. In Software and Techniques for Bio-Molecular Modelling, pp. 1-9. Austin Publishing Group.

RESEARCH PROJECT

National
  1. 2023 - 2026, Fundamental Research Grant Scheme (FRGS)
    Deep Learning In Molecular Descriptors Mining And Optimization For Drug-potentials Targeting G Protein-coupled Receptors ( Co-Researcher)
  2. 2022 - 2025, Fundamental Research Grant Scheme (FRGS)
    Investigating Factors Affecting Aptamer?s Conformation And Target Sensitivity At The Aptamer-graphene Interface And Mechanism Description For Biosensing Applications ( Co-Researcher)
  3. 2019 - 2023, Fundamental Research Grant Scheme (FRGS)
    Investigations Into The Poor Neutralization Efficacy Of Cobra Antivenom Against Lethal Cobra Neurotoxins Through In Vitro, In Vivo And In Silico Studies ( Co-Researcher)
  4. 2019 - 2022, Fundamental Research Grant Scheme (FRGS)
    A Mechanistic Study To Identify The Upstream Therapeutic Target Of Tribenzyltin Carboxylates For Improving Cancer Chemotherapy ( Principal Investigator(PI))
  5. 2019 - 2022, Fundamental Research Grant Scheme (FRGS)
    Unravelling The Antineoplastic Mechanism Of Anilinoquinazoline Compound In Lung Cancer Stem Cells And Zebrafish ( Co-Researcher)
  6. 2018 - 2021, RU Geran - Fakulti Program
    Multiscale Refinement Of Cryo-electron Microscopy Data For Structural Analysis And Mechanism Study Of Biological Macromolecules ( Co-Researcher)
  7. 2019 - 2021, Fundamental Research Grant Scheme (FRGS)
    In Silico Self-evolving Peptides Algorithm For The Discovery Of Potential Peptide Inhibitor Against Alpha-amylase And Alpha-glucosidase ( Principal Investigator(PI))
  8. 2016 - 2019, Postgraduate Research Grant (PPP) - Research
    Rational Discovery of Novel Hepatitis C Virus Inhibitors--An in silico approach targeting HCV serine protease and helicase ( Principal Investigator(PI))
  9. 2017 - 2019, Geran Penyelidikan Universiti Malaya (UMRG Programme) - AFR (Frontier Science)
    Insight Into The Binding Mechanism Of Quinazoline Derivatives Against Non-mutated And Mutated Egfrs ( Principal Investigator(PI))
  10. 2017 - 2018, Bantuan Khas Penyelidikan (BKP Special)
    Rational Discovery Of Novel Hepatitis C Virus Inhibitors ( Principal Investigator(PI))
  11. 2015 - 2017, Postgraduate Research Grant (PPP) - Research
    DEVELOPMENT OF A LIQUID CHROMATOGRAPHY MASS SPECTROMETRY (LCMS) METHOD FOR PHOSPHODIESTERASE-5 INHIBITORS ( Principal Investigator(PI))
  12. 2014 - 2016, Bantuan Kecil Penyelidikan (BKP)
    Discovery of Novel Inhibitors for Hepatitis C Virus via Virtual Screening ( Principal Investigator(PI))
Private
  1. 2015 - 2017, Private Funding
    Small Peptide Design For Anti Inflammatory Activity ( Principal Investigator(PI))
International
  1. 2021 - 2026, International Funding
    SATREPS : The Trilateral Collaboration Project for Anti-infectious Disease Drug Development: From Lead Optimization to Preclinical Testing ( Co-Researcher)

CONSULTANCY PROJECT

  • Facial Image Analysis Software 2.0, WINNOX COSMECEUTICS SDN BHD
    01 Jan 2024 - 31 Dec 2024 (National)
  • Eye Dark Circle Detection Software, Wipro Manufacturing Services Sdn. Bhd.
    01 Oct 2017 - 01 Oct 2018 (National)

PAPER PRESENTED

ORAL PRESENTER
  1. Self-Evolving Peptide Algorithm, Breakfast@UMHealth, Visibility, Information and Communication Unit, Faculty of Medicine (University) (12 Jul 2023 - 12 Jul 2023)
POSTER PRESENTER
  1. Insight into the Binding Mechanism of Quinazoline Derivatives against Non-mutated EGFRs for the Discovery of Anti-cancer Agent towards Non-small-cell Lung Cancer (Tan Ke Han), University Malaya Research Carnival, UM (University) (15 Nov 2018 - 16 Nov 2018)
  2. Rational Drug Discovery of Potential HCV Helicase Inhibitors, International Symposium on Grids & Clouds (ISGC) 2017, Academia Sinica (International) (05 Mar 2017 - 10 Mar 2017)
  3. Rational Discovery of Dengue Inhibitors, 7th HOPE Meeting, JSPS (International) (02 Mar 2015 - 06 Mar 2015)
PRESENTER
  1. Fragment-based Anti-zika Discovery, Nobelist Mindset Workshop 2016, UKM (National) (19 Sep 2016 - 23 Sep 2016)
OTHERS
  1. Rational discovery of anti-hepatitis c viral agent, Kyushu University UM Pharmacy Symposium 2018, Pharmacy Department, Faculty Medicine, University Malaya (International) (28 Nov 2018 - 28 Nov 2018)

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2016) Antimicrobial Peptide Susceptibility of Burkholderia Pseudomallei by Lee Lyn Fay, (Internal Examiner)
  2. (2016) Drug Design and Synthesis of COX-2 Selective Inhibitors as Potential NSAIDs by Abbeer A. Abdul Kader (SHC120031), (Internal Examiner)
  3. (2015) Drug Design and Synthesis of COX-2 Selective Inhibitors as Potential NSAIDs by Abbeer A. Abdul Kader (SHC120031), (Internal Examiner)
  4. (2015) Reviewer for MPS-PSC Abstracts, (Reviewer)

SUPERVISION

Postgraduate Student
PhD/ Doctoral
  1. (2023) INTEGRATIVE APPROACH TOWARDS THE DEVELOPMENT OF SPIROOXINDOLES AS POTENTIAL DENGUE VIRUS PROTEASE TYPE 2 INHIBITORS, KE HAN TAN
  2. (2023) Investigating the Neutralisation Efficacy of an Elapid Antivenom and Factors Affecting the Immunogenic Capacity of Alpha-Neurotoxins, CHAN YI WEI
  3. (2023) PEPTIDES GENERATION ALGORITHM TARGETING CANCER CELL SURFACE PROPERTIES: IN SILICO & IN VITRO STUDY, ZIRUI WANG
  4. (2020) SYNTHESIS OF NEW ANILINOQUINAZOLINE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS: ANTIPROLIFERATIVE ACTIVITY, MOLECULAR DOCKING AND MOLECULAR DYNAMICS STUDIES, MUHAMMAD KUMAYL BIN ABDUL WAHAB
  5. (2019) Rational Discovery of Novel NS3 Enzyme Inhibitors for Genotype 3 Hepatitis C Virus, LIM SEE KHAI
  6. (2015) Rational Discovery of Novel Hepatitis C Virus Inhibitors, Lim See Khai
Master
  1. (2023) Discovery of potential LRRK2 inhibitors through Al-assisted in silico approaches, CHUANCHENG WEI
  2. (2023) Evaluation of Potential Drug-Drug Interaction between Omeprazole and Anti-Diabetic Drug Linaglipitin in Silico and In Vitro analysis, JARIN TASNIM
  3. (2021) A REVERSED STRUCTURE-BASED PEPTIDE DESIGN OF HUMAN PAPILLOMAVIRUS E7 INHIBITOR, TAN WAN CHEIN
  4. (2021) IN SILICO STUDIES OF COMPETITIVE AND NON-COMPETITIVE EGFR-TK INHIBITORS IN LUNG CANCER, TAN KE HAN
  5. (2016) In Silico Design of Short Chain Peptide Inhibitor, ADIB AFANDI BIN ABDULLAH
  6. (2016) SIMULTANEOUS DETERMINATION OF PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS AND THEIR ANALOGUES IN SEXUAL ENHANCEMENT PRODUCTS, NUR BAIZURA BINTI BUJANG
  7. (2015) DEVELOPMENT OF A LIQUID CHROMATOGRAPHY MASS SPECTROMETRY (LC/MS) METHOD FOR SIMULATANEOUS DETERMINATION OF PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS, Nur Baizura Binti Bujang

TEACHING

Master
  1. (2024) OQB7005 - Pharmaceutical Bioinformatics
  2. (2023) OQB7006 - Advanced Medicinal Chemistry
Bachelor
  1. (2020) OIA1006 - Drug Action and Discovery
  2. (2020) OIA2001 - Medicinal Chemistry
  3. (2018) MIB3017 - Pharmaceutical Product Development
  4. (2018) MIB3019 - Drug Literacy
  5. (2017) MIB1001 - Basic Pharmaceutical Chemistry
  6. (2017) MIB3017 - Pharmaceutical Product Development
  7. (2016) MIB1008 - Physical Pharmacy
  8. (2016) MWEF1107 - Physical Pharmacy
  9. (2015) MIB1001 - Basic Pharmaceutical Chemistry
  10. (2015) MWEF1105 - Heterocyclic Chemistry & Drug Discovery
  11. (2015) MWEF1107 - Physical Pharmacy
  12. (2015) MWEF2102 - Pharmaceutical Analysis
  13. (2015) MWEF3106 - Pharmaceutical Product Development
  14. (2015) MWEF4104 - Hospital Pharmacy Services
  15. (2014) MWEF3106 - Pharmaceutical Product Development
  16. (2014) MWEF4103 - Clinical Pharmacy and Pharmacotherapy Ii

PATENT/IPR

  • Self-evolving Peptide Algorithm
    COPYRIGHT
  • A NOVEL DENGUE PROTEASE ASSAY KIT
    Patent (National)